Use of <scp>S</scp>orafenib as an effective treatment in an <scp>AML</scp> patient carrying a new point mutation affecting the <scp>J</scp>uxtamembrane domain of <i><scp>FLT</scp>3</i>Joaquín Martínez‐López, Rosa Ayala, Nerea Castro et al.|British Journal of Haematology|2012Cited by 5